- Home
- SBCWW vs CMMB Comparison
SBCWW vs CMMB Comparison
Compare SBCWW & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBCWW
- CMMB
- Stock Information
- Founded
- SBCWW N/A
- CMMB 2004
- Country
- SBCWW United States
- CMMB Israel
- Employees
- SBCWW N/A
- CMMB N/A
- Industry
- SBCWW Medical/Nursing Services
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- SBCWW Health Care
- CMMB Health Care
- Exchange
- SBCWW Nasdaq
- CMMB Nasdaq
- Market Cap
- SBCWW 19.1M
- CMMB 15.8M
- IPO Year
- SBCWW 2022
- CMMB N/A
- Fundamental
- Price
- SBCWW $0.16
- CMMB $1.51
- Analyst Decision
- SBCWW
- CMMB Strong Buy
- Analyst Count
- SBCWW 0
- CMMB 3
- Target Price
- SBCWW N/A
- CMMB $5.67
- AVG Volume (30 Days)
- SBCWW N/A
- CMMB 206.1K
- Earning Date
- SBCWW N/A
- CMMB 11-07-2024
- Dividend Yield
- SBCWW N/A
- CMMB N/A
- EPS Growth
- SBCWW N/A
- CMMB N/A
- EPS
- SBCWW N/A
- CMMB N/A
- Revenue
- SBCWW N/A
- CMMB N/A
- Revenue This Year
- SBCWW N/A
- CMMB N/A
- Revenue Next Year
- SBCWW N/A
- CMMB N/A
- P/E Ratio
- SBCWW N/A
- CMMB N/A
- Revenue Growth
- SBCWW N/A
- CMMB N/A
- 52 Week Low
- SBCWW N/A
- CMMB $0.42
- 52 Week High
- SBCWW N/A
- CMMB $2.55
- Technical
- Relative Strength Index (RSI)
- SBCWW N/A
- CMMB 43.28
- Support Level
- SBCWW N/A
- CMMB $1.29
- Resistance Level
- SBCWW N/A
- CMMB $1.58
- Average True Range (ATR)
- SBCWW 0.00
- CMMB 0.15
- MACD
- SBCWW 0.00
- CMMB -0.04
- Stochastic Oscillator
- SBCWW 0.00
- CMMB 39.29
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.